Bicaval TricValve Implantation in Patients With Severe Tricuspid Regurgitation
JACC: Cardiovascular Interventions · 2025-08 · 18 (15) · 1913-1924
DOI: 10.1016/j.jcin.2025.06.023 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2025-08. Verfasst von Angel Sánchez-Recalde und 38 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Ramon y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain. Electronic address: asrecalde@hotmail.com. Hauptthemen laut MEDLINE: Tricuspid Valve Insufficiency, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation, Tricuspid Valve. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Caval valve implantation is currently the only alternative for patients with severe tricuspid regurgitation (TR) who are deemed unsuitable candidates for transcatheter orthotopic therapies. OBJECTIVES: The aim of this study was to assess the efficacy and safety of TricValve system at 1-year follow-up. METHODS: TricBicaval registry is a multicenter registry that retrospectively enrolled all consecutive patients with severe TR treated with TricValve system. RESULTS: Of 204 patients included, 71.1% had renal insufficiency, 87.3% had massive or torrential TR, and 82.4% had TRI-SCOREs of ≥4 points. Intraprocedural success was 96.1%, and clinical success at 30 days was 83%. Functional class significantly improved with 19.8% of patients in NYHA functional class I or II at baseline vs 81.5% (P < 0.001) after a median follow-up period of 8.8 months (Q1-Q3: 1.5-12.3 months). A significant pressure reduction in the inferior vena cava was observed, alongside a marked decrease in signs of right heart failure. Heart failure hospitalizations significantly decreased during follow-up compared with the year preimplantation (60.8 [95% CI: 50.5-73.1] vs 26.9 [95% CI: 19.1-37.8] events per 100 patient-years; P < 0.001). At 1 year, the major adverse event rate was 19.1%, and mortality increased with increasing TRI-SCORE (0-3 points, 6.7% [95% CI: 1.7%-24.6%]; 4 or 5 points, 23.4% [95% CI: 14.4%-36.7%]; ≥6 points, 28.8% [95% CI: 19.8%-40.8%], log-rank P = 0.020). CONCLUSIONS: In this highly comorbid population with severe TR, caval valve implantation using the TricValve system led to significant 1-year clinical improvement, with mortality rates aligned with baseline TRI-SCORE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hospital Universitario Ramon y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain. Electronic address: asrecalde@hotmail.com.
- Hospital Universitario Ramon y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.
- Hartcentrum Aalst, Azorg, Aalst, Belgium.
- Hospital Universitario Clínico San Carlos, Madrid, Spain.
- University of Cologne, Faculty of Medicine and University Hospital Cologne, Clinic III for Internal Medicine, Cologne, Germany.
- Hospital Universitario de Valladolid, Valladolid, Spain; Centro de Investigación Biomédica En Red - Enfermedades Cardiovasculares, Instituto de Salud Carlos III, Madrid, Spain.
Zitieren
APA
Sánchez-Recalde, A., Domínguez-Rodríguez, L. M., Rosseel, L., Nombela-Franco, L., Pfister, R., Amat-Santos, I., Butter, C., Di Mauro, M., Cruz-González, I., Freixa, X., Swaans, M., Wilde, C., Cacela, D., Sarnago, F., Del Trigo, M., Estévez-Loureiro, R., López-Mínguez, J. R., De Torres-Alba, F., Montenegro, M., …, & Zamorano, J. L. (2025). Bicaval TricValve Implantation in Patients With Severe Tricuspid Regurgitation. JACC: Cardiovascular Interventions, 18(15), 1913-1924. https://doi.org/10.1016/j.jcin.2025.06.023
Vancouver
Sánchez-Recalde A, Domínguez-Rodríguez LM, Rosseel L, Nombela-Franco L, Pfister R, Amat-Santos I, et al. Bicaval TricValve Implantation in Patients With Severe Tricuspid Regurgitation. JACC: Cardiovascular Interventions. 2025;18(15):1913-1924. doi:10.1016/j.jcin.2025.06.023
BibTeX
@article{SnchezRecalde2025,
author = {Sánchez-Recalde, Angel and Domínguez-Rodríguez, Luis M and Rosseel, Liesbeth and Nombela-Franco, Luis and Pfister, Roman and Amat-Santos, Ignacio and Butter, Christian and Di Mauro, Michele and Cruz-González, Ignacio and Freixa, Xavier and Swaans, Martin and Wilde, Christoph and Cacela, Duarte and Sarnago, Fernando and Del Trigo, María and Estévez-Loureiro, Rodrigo and López-Mínguez, José Ramón and De Torres-Alba, Fernando and Montenegro, Marcio and Pérez-Fernández, Ruth and Guzman, Gabriela and Pajín, Fernando and Mylotte, Darren and Pan, Manuel and Kristoff, Cornelis and Carrillo-Suarez, Xavier and de la Torre, José María and Ruiz Quevedo, Valeriano and Salido, Luisa and Parraga, Rocio and Althoff, Jan and Fernández-Cordón, Clara and Guarracini, Stefano and Lopez-Tejero, Sergio and Abdul-Jawad Altisent, Omar and Lautenschläger, Lion and Ramos, Ruben and Puri, Rishi and Zamorano, José L},
title = {Bicaval TricValve Implantation in Patients With Severe Tricuspid Regurgitation},
journal = {JACC: Cardiovascular Interventions},
year = {2025},
volume = {18},
number = {15},
pages = {1913--1924},
doi = {10.1016/j.jcin.2025.06.023}
}
EUVIMED